Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib

Bookmark and Share
Published: 28 Sep 2014
Views: 2586
Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium

Dr Jean-Pascal Machiels of Cliniques Universitaires Saint-Luc, Brussels, Belgium talks to ecancertv at ESMO 2014 in Madrid Spain. He presents results from a phase III trial on the tyrosine kinase inhibitor, afatinib and the significant improvements it has shown in progression-free survival for patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy. 

Afatinib is a compound that irreversibly blocks the ErbB family of cell surface receptors, which includes epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), HER3 and HER4.

Read the news story or watch the press conference for more.